One of Germany’s main trade unions has pushed back against any future break-up of pharmaceutical and agrochemicals giant Bayer, claiming such a move would put thousands of
Bayer’s new chief executive Bill Anderson has launched a “re-design” of Bayer that will see layers of management stripped out by the end of next year, with “95% of the dec
AstraZeneca is looking at spinning out its Chinese operation and listing it in Hong Kong or Shanghai to insulate the business from rising geopolitical tension, according t
Sarah Rickwood delves into IQVIA data to find out exactly how pharma's HCP engagement has changed over COVID-19, and what the channel mix might look like after the pandemic.